Ares Financial Consulting’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$56.7K Sell
153
-10
-6% -$3.53K 0.04% 213
2026
Q2
$58.5K Buy
163
+10
+7% +$3.06K 0.04% 204
2026
Q1
$38.7K Buy
153
+147
+2,450% +$36.6K 0.03% 254
2025
Q4
$1.65K Buy
+6
New +$1.64K ﹤0.01% 689

Other funds holding WST

Ares Financial Consulting's WST Position: Q3 2026 in Review

Ares Financial Consulting reduced its West Pharmaceutical (WST) stake by 6.1% in Q3 2026, selling an estimated $3.53K and leaving 153 shares worth $56.7K. The position accounts for 0.04% of the portfolio, ranked #213.

Ares Financial Consulting first reported a position in WST in Q4 2025 and has held it in 4 quarters since. The position peaked at $58.5K in Q2 2026. 878 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • Ares Financial Consulting held 153 shares of West Pharmaceutical worth $56.7K as of Q3 2026.
  • Ares Financial Consulting sold 10 West Pharmaceutical shares in Q3 2026, an estimated $3.53K.
  • West Pharmaceutical made up 0.04% of Ares Financial Consulting's portfolio in Q3 2026, its #213 holding.
  • Ares Financial Consulting first reported a position in West Pharmaceutical in Q4 2025 and has held it in 4 quarters since.
  • Ares Financial Consulting's West Pharmaceutical position peaked at $58.5K in Q2 2026.
  • 878 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.